Literature DB >> 15988761

A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions.

Robert D Loberg1, Bishoy A Gayed, Karin B Olson, Kenneth J Pienta.   

Abstract

The pliability of cancer cells to mutate into several different phenotypes in an attempt to find one that will survive and colonize at the metastatic site is a tremendous "hurdle" to overcome in designing novel cancer therapeutics. New targets of therapy are essential if we are to effectively overcome the evasiveness of cancer. The interaction between the tumor cell and the surrounding microenvironment creates a vicious cycle that perpetuates disease survival and progression. The future of cancer therapy resides in the ability to focus on the recruited and exploited relationships of the cancer cell with the host environment. These therapies target cancer cell growth early and interrupt the vicious cycle that is created by the tumor cells interacting with bone components by inhibiting osteoclasts, osteoblasts, stromal cells, and endothelial cells. They alter the bone microenvironment, creating a hostile "soil" that prevents the "seed" from developing into bone metastases and represent a potential new platform for the development of prostate cancer therapeutics. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15988761     DOI: 10.1002/jcb.20522

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  16 in total

1.  Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.

Authors:  Mandeep S Virk; Farhang Alaee; Frank A Petrigliano; Osamu Sugiyama; Arion F Chatziioannou; David Stout; William C Dougall; Jay R Lieberman
Journal:  Bone       Date:  2010-11-10       Impact factor: 4.398

2.  Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.

Authors:  Xi Zhao; Anamika Bose; Hideo Komita; Jennifer L Taylor; Mayumi Kawabe; Nina Chi; Laima Spokas; Devin B Lowe; Christina Goldbach; Sean Alber; Simon C Watkins; Lisa H Butterfield; Pawel Kalinski; John M Kirkwood; Walter J Storkus
Journal:  Mol Ther       Date:  2010-12-28       Impact factor: 11.454

3.  Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis.

Authors:  Xiaotun Zhang; Wenbin Wang; Lawrence D True; Robert L Vessella; Thomas K Takayama
Journal:  Prostate       Date:  2009-05-15       Impact factor: 4.104

Review 4.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

Review 5.  Bone-targeting agents in prostate cancer.

Authors:  Daniel L Suzman; Sosipatros A Boikos; Michael A Carducci
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

6.  Matched pairs of human prostate stromal cells display differential tropic effects on LNCaP prostate cancer cells.

Authors:  Xiaojuan Sun; Hui He; Zhihui Xie; Weiping Qian; Haiyen E Zhau; Leland W K Chung; Fray F Marshall; Ruoxiang Wang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-04-10       Impact factor: 2.416

Review 7.  The multifaceted actions of PTHrP in skeletal metastasis.

Authors:  Fabiana N Soki; Serk In Park; Laurie K McCauley
Journal:  Future Oncol       Date:  2012-07       Impact factor: 3.404

8.  Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis.

Authors:  Fabiana N Soki; Amy J Koh; Jacqueline D Jones; Yeo Won Kim; Jinlu Dai; Evan T Keller; Kenneth J Pienta; Kamran Atabai; Hernan Roca; Laurie K McCauley
Journal:  J Biol Chem       Date:  2014-07-08       Impact factor: 5.157

9.  miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth.

Authors:  Ning Wang; Qi Li; Ning-Han Feng; Gong Cheng; Zhao-Long Guan; Yang Wang; Chao Qin; Chang-Jun Yin; Li-Xin Hua
Journal:  Asian J Androl       Date:  2013-08-26       Impact factor: 3.285

10.  Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1.

Authors:  H-F Yuen; Y-T Chiu; K-K Chan; Y-P Chan; C-W Chua; C M McCrudden; K-H Tang; M El-Tanani; Y-C Wong; X Wang; K-W Chan
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.